Supplements

RARE DISEASES REPORT: Cancers


 

Rare cancers, though individually rare by definition, impose a tremendous burden on adult and pediatric patient populations, especially when considering hematological cancers. In this Rare Diseases Report: Cancers , we bring you the latest information on new and ongoing developments in the treatment of some of these cancers through interviews with frontline researchers in the field.

In this issue:

  • Survey reveals special impact of COVID-19 on patients with rare disorders
  • New agents boost survival – and complexity – in chronic lymphocytic leukemia
  • Targeted therapies may alter the landscape of MCL treatment
  • Will CAR T push beyond lymphoma? There’s no guarantee

Read Now

Recommended Reading

First reported U.S. case of COVID-19 linked to Guillain-Barré syndrome
MDedge Hematology and Oncology
FDA approves new indications for pembrolizumab
MDedge Hematology and Oncology
ASCO says ‘no’ to home infusions of cancer treatment, with exceptions
MDedge Hematology and Oncology
COVID-19 prompts ‘democratization’ of cancer trials
MDedge Hematology and Oncology
Cancer disparities: One of the most pressing public health issues
MDedge Hematology and Oncology
The scope of under- and overtreatment in older adults with cancer
MDedge Hematology and Oncology
Clinical factors and treatment tied to COVID-19 mortality in cancer patients
MDedge Hematology and Oncology
CDER chief reflects on advances in rare diseases
MDedge Hematology and Oncology
Using telehealth to deliver palliative care to cancer patients
MDedge Hematology and Oncology
Childhood Hodgkin survivors have neurocognitive impairment
MDedge Hematology and Oncology